{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:07Z","timestamp":1792602907470,"version":"4.5.0"},"reference-count":215,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Glioblastoma is the most common malignant primary brain tumor in the adult population, with an average survival of 12.1 to 14.6 months. The standard treatment, combining surgery, radiotherapy, and chemotherapy, is not as efficient as we would like. However, the current possibilities are no longer limited to the standard therapies due to rapid advancements in biotechnology. New methods enable a more precise approach by targeting individual cells and antigens to overcome cancer. For the treatment of glioblastoma, these are gamma knife therapy, proton beam therapy, tumor-treating fields, EGFR and VEGF inhibitors, multiple RTKs inhibitors, and PI3K pathway inhibitors. In addition, the increasing understanding of the role of the immune system in tumorigenesis and the ability to identify tumor-specific antigens helped to develop immunotherapies targeting GBM and immune cells, including CAR-T, CAR-NK cells, dendritic cells, and immune checkpoint inhibitors. Each of the described methods has its advantages and disadvantages and faces problems, such as the inefficient crossing of the blood\u2013brain barrier, various neurological and systemic side effects, and the escape mechanism of the tumor. This work aims to present the current modern treatments of glioblastoma.<\/jats:p>","DOI":"10.3390\/ijms25115774","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T10:12:27Z","timestamp":1716804747000},"page":"5774","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches"],"prefix":"10.3390","volume":"25","author":[{"given":"Karol","family":"Sadowski","sequence":"first","affiliation":[{"name":"The Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004 Warsaw, Poland"},{"name":"Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-091 Warsaw, Poland"},{"name":"Centre for Preclinical Research, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8627-0601","authenticated-orcid":false,"given":"Adrianna","family":"Ja\u017cd\u017cewska","sequence":"additional","affiliation":[{"name":"The Department of Anatomy and Neurobiology, Medical University of Gdansk, D\u0119binki 1, 80-211 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Koz\u0142owski","sequence":"additional","affiliation":[{"name":"The Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7004-2351","authenticated-orcid":false,"given":"Aleksandra","family":"Zacny","sequence":"additional","affiliation":[{"name":"The Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9780-9484","authenticated-orcid":false,"given":"Tomasz","family":"Lorenc","sequence":"additional","affiliation":[{"name":"Department of Radiology I, The Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-0947","authenticated-orcid":false,"given":"Wioletta","family":"Olejarz","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-091 Warsaw, Poland"},{"name":"Centre for Preclinical Research, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1159\/000527437","article-title":"Primary Malignant Brain Tumors following Systemic Malignancies: A Population-Based Analysis","volume":"56","author":"Wang","year":"2022","journal-title":"Neuroepidemiology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Grochans, S., Cybulska, A.M., Simi\u0144ska, D., Korbecki, J., Kojder, K., Chlubek, D., and Baranowska-Bosiacka, I. (2022). Epidemiology of Glioblastoma Multiforme\u2013Literature Review. Cancers, 14.","DOI":"10.3390\/cancers14102412"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00401-020-02144-8","article-title":"Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features","volume":"139","author":"Sloan","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.14791\/btrt.2014.2.1.36","article-title":"Glioblastoma in a Patient with Neurofibromatosis Type 1: A Case Report and Review of the Literature","volume":"2","author":"Jeong","year":"2014","journal-title":"Brain Tumor Res. Treat."},{"key":"ref_5","first-page":"720273","article-title":"Turcot Syndrome: A Synchronous Clinical Presentation of Glioblastoma Multiforme and Adenocarcinoma of the Colon","volume":"2012","author":"Dipro","year":"2012","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.5603\/RPOR.a2022.0113","article-title":"Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: A retrospective study","volume":"27","author":"Mohammed","year":"2022","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5114\/jcb.2019.85722","article-title":"Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme","volume":"11","author":"Chatzikonstantinou","year":"2019","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5603\/PJNNS.a2021.0024","article-title":"Trends in glioblastoma treatment research: An analysis of clinical trials and literature","volume":"55","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41467-023-36005-1","article-title":"Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1586\/erm.12.30","article-title":"The cellular origin for malignant glioma and prospects for clinical advancements","volume":"12","author":"Zong","year":"2012","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20210922","DOI":"10.1098\/rsif.2021.0922","article-title":"Modelling glioma progression, mass effect and intracranial pressure in patient anatomy","volume":"19","author":"Menze","year":"2022","journal-title":"J. R. Soc. Interface"},{"key":"ref_12","first-page":"386","article-title":"Current data and strategy in glioblastoma multiforme","volume":"2","author":"Iacob","year":"2009","journal-title":"J. Med. Life"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2174\/187152011797378643","article-title":"Angiogenesis in glioblastoma multiforme: Navigating the maze","volume":"11","author":"Linkous","year":"2011","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_14","first-page":"307","article-title":"Glioblastoma multiforme\u2014An overview","volume":"18","author":"Szmidt","year":"2014","journal-title":"Contemp. Oncol."},{"key":"ref_15","unstructured":"Shan, F.Y., Zhao, D., Tirado, C.A., Fonkem, E., Zhang, Y.L., Feng, D.X., and Huang, J.H. (2022). Glioblastoma-Current Evidence, IntechOpen."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5114\/fn.2012.32361","article-title":"Established and emerging variants of glioblastoma multiforme: Review of morphological and molecular features","volume":"50","author":"Karsy","year":"2012","journal-title":"Folia Neuropathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/1097-0142(19890515)63:10<2014::AID-CNCR2820631025>3.0.CO;2-L","article-title":"Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies","volume":"63","author":"Burger","year":"1989","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00005072-200606000-00001","article-title":"\u2018Pseudopalisading\u2019 necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis","volume":"65","author":"Rong","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1002\/cncr.23899","article-title":"Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: A comparative morphologic and molecular genetic study","volume":"113","author":"Rodriguez","year":"2008","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00401-010-0736-4","article-title":"Molecular diagnostics of gliomas: State of the art","volume":"120","author":"Riemenschneider","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/1097-0142(19890201)63:3<524::AID-CNCR2820630321>3.0.CO;2-D","article-title":"Giant-celled glioblastoma of brain. A clinico-pathological and radiological study of ten cases (including immunohistochemistry and ultrastructure)","volume":"63","author":"Margetts","year":"1989","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00401-018-1905-0","article-title":"Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma","volume":"136","author":"Stichel","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/0973-1482.48769","article-title":"Butterfly glioma of the corpus callosum","volume":"5","author":"Agrawal","year":"2009","journal-title":"J. Cancer Res. Ther."},{"key":"ref_25","first-page":"505","article-title":"Tubulin targets in the pathobiology and therapy of glioblastoma multiforme","volume":"221","author":"Katsetos","year":"2009","journal-title":"I. class III \u03b2-tubulin. J. Cell Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-6413-2-19","article-title":"Fine needle aspiration diagnosis of extracranial glioblastoma multiforme: Case report and review of the literature","volume":"2","author":"Schultz","year":"2005","journal-title":"Cytojournal"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The Definition of Primary and Secondary Glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/RMR.0000000000000234","article-title":"Adult Glioma WHO Classification Update, Genomics, and Imaging: What the Radiologists Need to Know","volume":"29","author":"Bai","year":"2020","journal-title":"Top. Magn. Reson. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Genc, S., Pennisi, M., Yeni, Y., Yildirim, S., Gattuso, G., Altinoz, M.A., Taghizadehghalehjoughi, A., Bolat, I., Tsatsakis, A., and Hac\u0131m\u00fcft\u00fco\u011flu, A. (2022). Potential Neurotoxic Effects of Glioblastoma-Derived Exosomes in Primary Cultures of Cerebellar Neurons via Oxidant Stress and Glutathione Depletion. Antioxidants, 11.","DOI":"10.3390\/antiox11071225"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Yalamarty, S.S.K., Filipczak, N., Li, X., Subhan, A., Parveen, F., Ataide, J.A., Rajmalani, B.A., and Torchilin, V.P. (2023). Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). Cancers, 15.","DOI":"10.3390\/cancers15072116"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/cncr.21539","article-title":"A population-based description of glioblastoma multiforme in Los Angeles County, 1974\u20131999","volume":"104","author":"Chakrabarti","year":"2005","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO Classification of Tumours of the Central Nervous System","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/B978-0-12-802997-8.00023-2","article-title":"Glioblastoma","volume":"134","author":"Wirsching","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1002\/ctm2.997","article-title":"Glioblastoma-educated mesenchymal stem-like cells promote glioblastoma infiltration via extracellular matrix remodelling in the tumour microenvironment","volume":"12","author":"Kim","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_35","first-page":"24","article-title":"Glioblastoma: Changing concepts in the WHO CNS5 classification","volume":"65","author":"Chen","year":"2022","journal-title":"Indian J. Pathol. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-011-0793-0","article-title":"Recent advances in the molecular understanding of glioblastoma","volume":"108","author":"Bleeker","year":"2012","journal-title":"J. Neuro-Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Becker, A.P., Sells, B.E., Haque, S.J., and Chakravarti, A. (2021). Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. Cancers, 13.","DOI":"10.3390\/cancers13040761"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","article-title":"Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Fisher, J.P., and Adamson, D.C. (2021). Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030324"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5732\/cjc.013.10219","article-title":"Novel strategies in glioblastoma surgery aim at safe, supra-maximum resection in conjunction with local therapies","volume":"33","author":"Wolbers","year":"2014","journal-title":"Chin. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1212\/01.wnl.0000345668.03039.90","article-title":"Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience","volume":"72","author":"Nghiemphu","year":"2009","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11864-016-0422-4","article-title":"Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences","volume":"17","author":"Tosoni","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clineuro.2016.01.010","article-title":"Second surgery for recurrent glioblastoma: A concise overview of the current literature","volume":"142","author":"Montemurro","year":"2016","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0360-3016(96)00455-5","article-title":"Hypofractionated stereotactic radiotherapy in the management of recurrent glioma","volume":"37","author":"Shepherd","year":"1997","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/cns.15.2","article-title":"Chemotherapy in glioma","volume":"4","author":"Taal","year":"2015","journal-title":"CNS Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/0008-5472.CAN-11-0153","article-title":"Heterogeneity Maintenance in Glioblastoma: A Social Network","volume":"71","author":"Bonavia","year":"2011","journal-title":"Cancer Res."},{"key":"ref_50","first-page":"992","article-title":"Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture","volume":"42","author":"Yung","year":"1982","journal-title":"Cancer Res."},{"key":"ref_51","first-page":"105","article-title":"Tumor heterogeneity: Causes and consequences","volume":"1805","author":"Marusyk","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/carcin\/bgq087","article-title":"Models of carcinogenesis: An overview","volume":"31","author":"Vineis","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"ref_54","first-page":"21","article-title":"Cancer Stem Cell Hierarchy in Glioblastoma Multiforme","volume":"3","author":"Bradshaw","year":"2016","journal-title":"Front. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","article-title":"Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment","volume":"13","author":"Cahill","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Nickel, G.C., Barnholtz-Sloan, J., Gould, M.P., McMahon, S., Cohen, A., Adams, M.D., Guda, K., Cohen, M., Sloan, A.E., and LaFramboise, T. (2012). Characterizing Mutational Heterogeneity in a Glioblastoma Patient with Double Recurrence. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035262"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1158\/0008-5472.CAN-10-0076","article-title":"A microfluidic platform for systems pathology: Multiparameter single-cell signaling measurements of clinical brain tumor specimens","volume":"70","author":"Sun","year":"2010","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/jnnp.46.9.797","article-title":"Stereotactic radiosurgery","volume":"46","author":"Leksell","year":"1983","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Albano, L., Losa, M., Barzaghi, L.R., Niranjan, A., Siddiqui, Z., Flickinger, J.C., Lunsford, L.D., and Mortini, P. (2021). Gamma Knife Radiosurgery for Pituitary Tumors: A Systematic Review and Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13194998"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11060-018-2988-0","article-title":"Gamma knife radiosurgery for recurrent gliomas","volume":"140","author":"Sadik","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4103\/0028-3886.284356","article-title":"Role of Gamma Knife Radiosurgery in the Management of Intracranial Gliomas","volume":"68","author":"Tripathi","year":"2020","journal-title":"Neurol. India"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00006123-199710000-00004","article-title":"Survival Benefit of Stereotactic Radiosurgery for Patients with Malignant Glial Neoplasms","volume":"41","author":"Kondziolka","year":"1997","journal-title":"Neurosurgery"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","article-title":"Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol","volume":"60","author":"Souhami","year":"2004","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.3171\/foc.2006.20.4.11","article-title":"Gamma knife surgery for glioblastoma multiforme","volume":"20","author":"Crowley","year":"2006","journal-title":"Neurosurg. Focus"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/cncr.23402","article-title":"Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas","volume":"112","author":"Kong","year":"2008","journal-title":"Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.wneu.2012.03.024","article-title":"Gamma Knife Surgery versus Reoperation for Recurrent Glioblastoma Multiforme","volume":"78","author":"Skeie","year":"2012","journal-title":"World Neurosurg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13014-017-0924-7","article-title":"Treatment of meningioma and glioma with protons and carbon ions","volume":"12","author":"Adeberg","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13045-018-0683-4","article-title":"Proton beam therapy for cancer in the era of precision medicine","volume":"11","author":"Hu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11060-016-2228-4","article-title":"Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: Comparison of nimustine hydrochloride and temozolomide","volume":"130","author":"Mizumoto","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Fabian, D., Eibl, M.d.P.G.P., Alnahhas, I., Sebastian, N., Giglio, P., Puduvalli, V., Gonzalez, J., and Palmer, J.D. (2019). Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. Cancers, 11.","DOI":"10.3390\/cancers11020174"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Guo, X., Yang, X., Wu, J., Yang, H., Li, Y., Li, J., Liu, Q., Wu, C., Xing, H., and Liu, P. (2022). Tumor-Treating Fields in Glioblastomas: Past, Present, and Future. Cancers, 14.","DOI":"10.3390\/cancers14153669"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1179554918825449","DOI":"10.1177\/1179554918825449","article-title":"Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune((R)) System","volume":"13","author":"Kinzel","year":"2019","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3171\/2016.9.JNS16452","article-title":"Alternating electric tumor treating fields for treatment of glioblastoma: Rationale, preclinical, and clinical studies","volume":"128","author":"Mittal","year":"2018","journal-title":"J. Neurosurg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/neuonc\/now260","article-title":"LTBK-01: Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in patients with newly diagnosed glioblastoma","volume":"18","author":"Stupp","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs. Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10143-016-0727-6","article-title":"The role of brachytherapy in the treatment of glioblastoma multiforme","volume":"40","author":"Barbarite","year":"2016","journal-title":"Neurosurg. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"110012","DOI":"10.1016\/j.radonc.2023.110012","article-title":"Brachytherapy is an effective and safe salvage option for re-irradiation in recurrent glioblastoma (rGBM): A systematic review","volume":"190","author":"Xiang","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3389\/fonc.2019.00963","article-title":"Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets","volume":"9","author":"Taylor","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s41467-021-21613-6","article-title":"Structure\u2013function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting","volume":"12","author":"Du","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Rodriguez, S.M.B., Kamel, A., Ciubotaru, G.V., Onose, G., Sevastre, A.-S., Sfredel, V., Danoiu, S., Dricu, A., and Tataranu, L.G. (2023). An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241311110"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijrobp.2010.01.070","article-title":"Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo\/North Central Cancer Treatment Group Study N0074","volume":"80","author":"Uhm","year":"2011","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","article-title":"Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme","volume":"98","author":"Peereboom","year":"2009","journal-title":"J. Neuro-Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/neuonc\/nop015","article-title":"A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy","volume":"12","author":"Raizer","year":"2009","journal-title":"Neuro-Oncology"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Pan, P.C., and Magge, R.S. (2020). Mechanisms of EGFR Resistance in Glioblastoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228471"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Cruz Da Silva, E., Mercier, M.C., Etienne-Selloum, N., Dontenwill, M., and Choulier, L. (2021). A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers, 13.","DOI":"10.3390\/cancers13081795"},{"key":"ref_90","first-page":"430","article-title":"Phase I\/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma","volume":"17","author":"Reardon","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/neuonc\/nox105","article-title":"Phase II trial of dacomitinib, a pan\u2013human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification","volume":"19","author":"Vaz","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"viii14","DOI":"10.1093\/neuonc\/nou222","article-title":"Challenges to targeting epidermal growth factor receptor in glioblastoma: Escape mechanisms and combinatorial treatment strategies","volume":"16","author":"Roth","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00280-009-1041-6","article-title":"A phase I\/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: Clinical outcomes, pharmacokinetics and molecular correlation","volume":"65","author":"Thiessen","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.2174\/138161211797249233","article-title":"Targeting ErbB Receptors in High-Grade Glioma","volume":"17","author":"Berezowska","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1517\/14712590903110709","article-title":"Nimotuzumab: A novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity","volume":"9","author":"Boland","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_96","first-page":"508","article-title":"Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial","volume":"12","author":"Hasselbalch","year":"2010","journal-title":"Neuro-Oncology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/annonc\/mdp032","article-title":"Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma","volume":"20","author":"Neyns","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_99","first-page":"587","article-title":"Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors","volume":"43","author":"Narita","year":"2013","journal-title":"Ultrasound Med. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/13543784.2019.1650019","article-title":"The evolving role of antiangiogenic therapies in glioblastoma multiforme: Current clinical significance and future potential","volume":"28","author":"Anthony","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.ccell.2022.08.014","article-title":"Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity","volume":"40","author":"Chryplewicz","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus Radiotherapy\u2013Temozolomide for Newly Diagnosed Glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5114\/wo.2020.94726","article-title":"Receptor tyrosine kinase targeting in glioblastoma: Performance, limitations and future approaches","volume":"24","author":"Alexandru","year":"2020","journal-title":"Wspolczesna Onkol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Olejarz, W., Sadowski, K., and Radoszkiewicz, K. (2023). Extracellular Vesicles in Atherosclerosis: State of the Art. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010388"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","article-title":"Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma","volume":"20","author":"Snuderl","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1200\/JCO.2008.16.9235","article-title":"Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study","volume":"26","author":"Raymond","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11060-009-9976-3","article-title":"Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide","volume":"96","author":"Dresemann","year":"2009","journal-title":"J. Neuro-Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.apsb.2021.12.019","article-title":"Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds","volume":"12","author":"Liu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/neuonc\/nos117","article-title":"Current clinical development of PI3K pathway inhibitors in glioblastoma","volume":"14","author":"Wen","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s13277-013-0800-5","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in glioblastoma: Novel therapeutic agents and advances in understanding","volume":"34","author":"Sami","year":"2013","journal-title":"Tumor Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"33440","DOI":"10.18632\/oncotarget.7961","article-title":"PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Ghafouri-Fard, S., Abak, A., Shoorei, H., Mohaqiq, M., Majidpoor, J., Sayad, A., and Taheri, M. (2020). Regulatory role of microRNAs on PTEN signaling. Biomed. Pharmacother., 133.","DOI":"10.1016\/j.biopha.2020.110986"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Behrooz, A.B., Talaie, Z., Jusheghani, F., \u0141os, M.J., Klonisch, T., and Ghavami, S. (2022). Wnt and PI3K\/Akt\/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031353"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1078-0432.CCR-11-1558","article-title":"Antitumor activity of NVP-BKM120\u2014A selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells","volume":"18","author":"Koul","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.18.01207","article-title":"Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial","volume":"37","author":"Wen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_117","first-page":"1270","article-title":"Phase II study of PX-866 in recurrent glioblastoma","volume":"17","author":"Pitz","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/neuonc\/nox209","article-title":"A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Sadowski, K., Olejarz, W., and Basak, G. (2022). Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232315006"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.2147\/IJGM.S418837","article-title":"Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma","volume":"16","author":"Liang","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11060-020-03448-1","article-title":"A review of glioblastoma immunotherapy","volume":"151","author":"Medikonda","year":"2021","journal-title":"J. Neuro-Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Maggs, L., Cattaneo, G., Dal, A.E., Moghaddam, A.S., and Ferrone, S. (2021). CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.662064"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"Nasrallah","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Staff, P.O. (2018). Correction: Glioma IL13Ralpha2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204463"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1092587","DOI":"10.1155\/2019\/1092587","article-title":"EGFR(vIII): An Oncogene with Ambiguous Role","volume":"2019","author":"Rutkowska","year":"2019","journal-title":"J. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-007-9424-1","article-title":"Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma","volume":"85","author":"Mineo","year":"2007","journal-title":"J. Neuro-Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific Chimeric Antigen Receptor\u2013Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"srep39833","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.3389\/fimmu.2019.02683","article-title":"CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy","volume":"10","author":"Burger","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Li, Y., Sharma, A., Maciaczyk, J., and Schmidt-Wolf, I.G.H. (2022). Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031311"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12\/SDF-1alpha-secreting Glioblastoma","volume":"38","author":"Michen","year":"2015","journal-title":"J. Immunother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e1119354","DOI":"10.1080\/2162402X.2015.1119354","article-title":"Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival","volume":"5","author":"Burger","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/0008-5472.CAN-12-2609","article-title":"Focused Ultrasound Delivers Targeted Immune Cells to Metastatic Brain Tumors","volume":"73","author":"Alkins","year":"2013","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Xiong, Z., Raphael, I., Olin, M., Okada, H., Li, X., and Kohanbash, G. (2024). Glioblastoma vaccines: Past, present, and opportunities. EBioMedicine, 100.","DOI":"10.1016\/j.ebiom.2023.104963"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/21645515.2017.1388481","article-title":"Vaccination in the immunotherapy of glioblastoma","volume":"14","author":"Kong","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1146\/annurev-immunol-101819-025146","article-title":"Dendritic Cell Regulation of T Helper Cells","volume":"39","author":"Yin","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","article-title":"Dendritic Cells Revisited","volume":"39","author":"Cardoso","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0306-4522(96)00160-1","article-title":"The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system","volume":"74","author":"Matyszak","year":"1996","journal-title":"Neuroscience"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0165-5728(99)00240-4","article-title":"Monocyte-derived IL-10-secreting dendritic cells in choroid plexus epithelium","volume":"105","author":"Serot","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1096-9861(19990322)405:4<553::AID-CNE8>3.0.CO;2-6","article-title":"Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations","volume":"405","author":"McMenamin","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"ref_149","first-page":"887","article-title":"Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte\/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor alpha","volume":"200","author":"Sallusto","year":"2018","journal-title":"J. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1200\/JCO.2000.18.23.3894","article-title":"Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells","volume":"18","author":"Small","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-019-0580-6","article-title":"The clinical application of cancer immunotherapy based on naturally circulating dendritic cells","volume":"7","author":"Bol","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0165-5728(99)00172-1","article-title":"Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma","volume":"103","author":"Heimberger","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"ref_153","first-page":"8487","article-title":"Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model","volume":"63","author":"Prins","year":"2003","journal-title":"Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-006-0138-6","article-title":"Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas","volume":"55","author":"Ciesielski","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_155","first-page":"613","article-title":"A dendritic cell vaccine induces protective immunity to intracranial growth of glioma","volume":"22","author":"Insug","year":"2002","journal-title":"Anticancer. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s002620100220","article-title":"Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor","volume":"50","author":"Aoki","year":"2001","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006452726391","article-title":"Immunization with Dendritic Cells Pulsed with Tumor Extract Increases Survival of Mice Bearing Intracranial Gliomas","volume":"51","author":"Ni","year":"2001","journal-title":"J. Neuro-Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11060-004-3339-x","article-title":"An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats","volume":"74","author":"Zhu","year":"2005","journal-title":"J. Neuro-Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1158\/0008-5472.CAN-06-2048","article-title":"Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas","volume":"66","author":"Pellegatta","year":"2006","journal-title":"Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1179\/016164106X116809","article-title":"Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice","volume":"28","author":"Pellegatta","year":"2006","journal-title":"Neurol. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00262-008-0510-9","article-title":"Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma","volume":"57","author":"Ciesielski","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1158\/0008-5472.CAN-08-2915","article-title":"Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10","volume":"69","author":"Fujita","year":"2009","journal-title":"Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3389\/fimmu.2018.00727","article-title":"Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme","volume":"9","author":"Jan","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-05-0464","article-title":"Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment","volume":"11","author":"Liau","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1158\/1078-0432.CCR-07-4875","article-title":"Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme","volume":"14","author":"Fieuws","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e23401","DOI":"10.4161\/onci.23401","article-title":"The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates","volume":"2","author":"Pellegatta","year":"2013","journal-title":"OncoImmunology"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Buchroithner, J., Erhart, F., Pichler, J., Widhalm, G., Preusser, M., Stockhammer, G., Nowosielski, M., Iglseder, S., Freyschlag, C.F., and Oberndorfer, S. (2018). Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. Cancers, 10.","DOI":"10.3390\/cancers10100372"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.wneu.2011.08.020","article-title":"Adjuvant Immunotherapy with Whole-Cell Lysate Dendritic Cells Vaccine for Glioblastoma Multiforme: A Phase II Clinical Trial","volume":"77","author":"Cho","year":"2011","journal-title":"World Neurosurg."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12013-011-9265-6","article-title":"Clinical Application of a Dendritic Cell Vaccine Raised Against Heat-Shocked Glioblastoma","volume":"62","author":"Jie","year":"2011","journal-title":"Cell Biochem. Biophys."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00262-018-2232-y","article-title":"Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: An exploratory randomized phase II clinical trial","volume":"67","author":"Yao","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","article-title":"A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma","volume":"25","author":"Wen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-20-1082","article-title":"Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma","volume":"26","author":"Batich","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nri3265","article-title":"The anatomical and cellular basis of immune surveillance in the central nervous system","volume":"12","author":"Ransohoff","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/neuonc\/nop024","article-title":"Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment","volume":"12","author":"Pellegatta","year":"2010","journal-title":"Neuro-Oncology"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF01742258","article-title":"Factors, including transforming growth factor \u03b2, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells","volume":"36","author":"Ruffini","year":"1993","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1158\/1078-0432.CCR-17-0077","article-title":"Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNbeta in Glioblastomas","volume":"23","author":"Choi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/00001756-200507130-00010","article-title":"B7-homolog 1 expression by human glioma: A new mechanism of immune evasion","volume":"16","author":"Wilmotte","year":"2005","journal-title":"Neuroreport"},{"key":"ref_180","first-page":"7462","article-title":"Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis","volume":"63","author":"Wintterle","year":"2003","journal-title":"Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"srep33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","article-title":"Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors","volume":"20","author":"Wainwright","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11060-017-2466-0","article-title":"Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: A retrospective case series","volume":"133","author":"Chamberlain","year":"2017","journal-title":"J. Neuro-Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs. Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"676301","DOI":"10.3389\/fimmu.2021.676301","article-title":"Immunotherapy for Glioblastoma: Current Progress and Challenges","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_191","first-page":"454","article-title":"Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti\u2013PD-1 treatment with nivolumab","volume":"19","author":"Roth","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","article-title":"IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival","volume":"18","author":"Wainwright","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: Lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5306\/wjco.v14.i4.138","article-title":"Immunotherapy in glioblastoma treatment: Current state and future prospects","volume":"14","author":"Pinheiro","year":"2023","journal-title":"World J. Clin. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2055417","DOI":"10.1080\/21645515.2022.2055417","article-title":"Immunotherapy of glioblastoma: Recent advances and future prospects","volume":"18","author":"Yuan","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/21645515.2015.1037058","article-title":"Oncolytic viruses: From bench to bedside with a focus on safety","volume":"11","author":"Buijs","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood-brain barrier: An overview: Structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/j.1471-4159.1985.tb07167.x","article-title":"Human Blood\u2014Brain Barrier Insulin Receptor","volume":"44","author":"Pardridge","year":"1985","journal-title":"J. Neurochem."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s004010000180","article-title":"Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme","volume":"100","author":"Liebner","year":"2000","journal-title":"Acta Neuropathol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0736-5748(99)00008-8","article-title":"Scatter factor\/hepatocyte growth factor (SF\/HGF) content and function in human gliomas","volume":"17","author":"Lamszus","year":"1999","journal-title":"Int. J. Dev. Neurosci."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00401-012-1066-5","article-title":"Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited","volume":"124","author":"Plate","year":"2012","journal-title":"Acta Neuropathol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.drudis.2008.09.005","article-title":"The targeted delivery of cancer drugs across the blood-brain barrier: Chemical modifications of drugs or drug-nanoparticles?","volume":"13","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"He, Q., Liu, J., Liang, J., Liu, X., Li, W., Liu, Z., Ding, Z., and Tuo, D. (2018). Towards Improvements for Penetrating the Blood\u2013Brain Barrier\u2014Recent Progress from a Material and Pharmaceutical Perspective. Cells, 7.","DOI":"10.3390\/cells7040024"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Hsu, J.-F., Chu, S.-M., Liao, C.-C., Wang, C.-J., Wang, Y.-S., Lai, M.-Y., Wang, H.-C., Huang, H.-R., and Tsai, M.-H. (2021). Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update. Cancers, 13.","DOI":"10.3390\/cancers13020195"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"64","DOI":"10.15212\/bioi-2020-0003","article-title":"Enhancing Chemotherapy by RNA Interference","volume":"1","author":"Cao","year":"2020","journal-title":"BIO Integr."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.celrep.2017.10.030","article-title":"Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma","volume":"21","author":"Darmanis","year":"2017","journal-title":"Cell Rep."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Ou, A., Yung, W.K.A., and Majd, N. (2020). Molecular Mechanisms of Treatment Resistance in Glioblastoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010351"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3171\/jns.2002.96.3.0580","article-title":"Apoptosis of T lymphocytes invading glioblastomas multiforme: A possible tumor defense mechanism","volume":"96","author":"Didenko","year":"2002","journal-title":"J. Neurosurg."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5774\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:48:55Z","timestamp":1760107735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,26]]},"references-count":215,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25115774"],"URL":"https:\/\/doi.org\/10.3390\/ijms25115774","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,26]]}}}